These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 8495279

  • 1. Dose-dependent effects of deflazacort and prednisone on growth and skeletal maturation.
    Aicardi G, Benso L, Vignolo M, Terragna A, Verrina E, Cordone G, Coppo R, Sernia O, Sardella ML, Di Battista E.
    Br J Rheumatol; 1993 May; 32 Suppl 2():39-43. PubMed ID: 8495279
    [Abstract] [Full Text] [Related]

  • 2. Comparison of growth retarding effects induced by two different glucocorticoids in prepubertal sick children: an interim long-term analysis.
    Aicardi G, Milani S, Imbimbo B, Vignolo M, Di Battista E, Gusmano R, Terragna A, Cordone G, Cottafava F, Coppo R.
    Calcif Tissue Int; 1991 Apr; 48(4):283-7. PubMed ID: 2059880
    [Abstract] [Full Text] [Related]

  • 3. Statural growth and skeletal maturation in rheumatic prepubertal children treated with a third generation glucocorticoid (deflazacort) versus prednisone. An interim study.
    Vignolo M, Milani S, Imbimbo B, Naselli A, Di Battista E, Piaggio G, Leveratto L, Morreale G, Sardella ML, Corsini M.
    Clin Exp Rheumatol; 1991 Apr; 9 Suppl 6():41-5. PubMed ID: 2060177
    [Abstract] [Full Text] [Related]

  • 4. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone versus deflazacort.
    Olgaard K, Storm T, van Wowern N, Daugaard H, Egfjord M, Lewin E, Brandi L.
    Calcif Tissue Int; 1992 Jun; 50(6):490-7. PubMed ID: 1525702
    [Abstract] [Full Text] [Related]

  • 5. The long-term efficacy and safety of two different corticosteroids in chronic sarcoidosis.
    Rizzato G, Riboldi A, Imbimbo B, Torresin A, Milani S.
    Respir Med; 1997 Sep; 91(8):449-60. PubMed ID: 9338047
    [Abstract] [Full Text] [Related]

  • 6. A controlled study of deflazacort in the treatment of idiopathic nephrotic syndrome.
    Broyer M, Terzi F, Lehnert A, Gagnadoux MF, Guest G, Niaudet P.
    Pediatr Nephrol; 1997 Aug; 11(4):418-22. PubMed ID: 9260237
    [Abstract] [Full Text] [Related]

  • 7. Effects of long-term maintenance therapy with a new glucocorticoid, deflazacort, on mineral metabolism and statural growth.
    Balsan S, Stéru D, Bourdeau A, Grimberg R, Lenoir G.
    Calcif Tissue Int; 1987 Jun; 40(6):303-9. PubMed ID: 3111667
    [Abstract] [Full Text] [Related]

  • 8. Deflazacort induced stronger immunosuppression than expected.
    Gonzalez-Castañeda RE, Castellanos-Alvarado EA, Flores-Marquez MR, Gonzalez-Perez O, Luquin S, Garcia-Estrada J, Ramos-Remus C.
    Clin Rheumatol; 2007 Jun; 26(6):935-40. PubMed ID: 16738843
    [Abstract] [Full Text] [Related]

  • 9. Experience with deflazacort in children and adolescents after renal transplantation.
    Schärer K, Feneberg R, Klaus G, Paschen C, Wüster C, Mehls O, Schaefer F.
    Pediatr Nephrol; 2000 Jun; 14(6):457-63. PubMed ID: 10872183
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.
    Griggs RC, Miller JP, Greenberg CR, Fehlings DL, Pestronk A, Mendell JR, Moxley RT, King W, Kissel JT, Cwik V, Vanasse M, Florence JM, Pandya S, Dubow JS, Meyer JM.
    Neurology; 2016 Nov 15; 87(20):2123-2131. PubMed ID: 27566742
    [Abstract] [Full Text] [Related]

  • 11. Potency ratio--a brief synopsis.
    Avioli LV.
    Br J Rheumatol; 1993 May 15; 32 Suppl 2():24-6. PubMed ID: 8495276
    [Abstract] [Full Text] [Related]

  • 12. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.
    Bello L, Gordish-Dressman H, Morgenroth LP, Henricson EK, Duong T, Hoffman EP, Cnaan A, McDonald CM, CINRG Investigators.
    Neurology; 2015 Sep 22; 85(12):1048-55. PubMed ID: 26311750
    [Abstract] [Full Text] [Related]

  • 13. Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy.
    Lamb MM, West NA, Ouyang L, Yang M, Weitzenkamp D, James K, Ciafaloni E, Pandya S, DiGuiseppi C, Muscular Dystrophy Surveillance, Research, and Tracking Network (MD STARnet).
    J Pediatr; 2016 Jun 22; 173():207-213.e3. PubMed ID: 27039228
    [Abstract] [Full Text] [Related]

  • 14. Deflazacort in juvenile chronic arthritis.
    Loftus JK, Reeve J, Hesp R, David J, Ansell BM, Woo PM.
    J Rheumatol Suppl; 1993 Apr 22; 37():40-2. PubMed ID: 8501751
    [Abstract] [Full Text] [Related]

  • 15. Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases.
    Scudeletti M, Puppo F, Lanza L, Mantovani L, Bosco O, Iudice A, Imbimbo B, Indiveri F.
    Eur J Clin Pharmacol; 1993 Apr 22; 45 Suppl 1():S29-34. PubMed ID: 8313931
    [Abstract] [Full Text] [Related]

  • 16. Differential effect of glucocorticoids on calcium absorption and bone mass.
    Gennari C.
    Br J Rheumatol; 1993 May 22; 32 Suppl 2():11-4. PubMed ID: 8495275
    [Abstract] [Full Text] [Related]

  • 17. Deflazacort versus prednisone in patients with giant cell arteritis: effects on bone mass loss.
    Cacoub P, Chemlal K, Khalifa P, Wechsler B, De Gennes C, Belmatoug N, Cohen P, Ziza JM, Verdoncq B, Piette JC.
    J Rheumatol; 2001 Nov 22; 28(11):2474-9. PubMed ID: 11708421
    [Abstract] [Full Text] [Related]

  • 18. Randomized, double-blind trial of deflazacort versus prednisone in juvenile chronic (or rheumatoid) arthritis: a relatively bone-sparing effect of deflazacort.
    Loftus J, Allen R, Hesp R, David J, Reid DM, Wright DJ, Green JR, Reeve J, Ansell BM, Woo PM.
    Pediatrics; 1991 Sep 22; 88(3):428-36. PubMed ID: 1881719
    [Abstract] [Full Text] [Related]

  • 19. Head to head comparison of adverse effects and efficacy between high dose deflazacort and high dose prednisolone in systemic lupus erythematosus: a prospective cohort study.
    Ganapati A, Ravindran R, David T, Yadav B, Jeyaseelan V, Jeyaseelan L, Danda D.
    Lupus; 2018 May 22; 27(6):890-898. PubMed ID: 29320974
    [Abstract] [Full Text] [Related]

  • 20. Deflazacort for the treatment of Duchenne Dystrophy: a systematic review.
    Campbell C, Jacob P.
    BMC Neurol; 2003 Sep 08; 3():7. PubMed ID: 12962544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.